Interim estimates of influenza vaccine effectiveness in 2012/13 from Canada’s sentinel surveillance network, January 2013

D M Skowronski; N Z Janjua; G De Serres; J A Dickinson; A-L Winter; S M Mahmud; S Sabaiduc; J B Gubbay; H Charest; M Petric; K Fonseca; P Van Caeseele; T L Kwindt; M Krajden; A Eshaghi; Y Li

doi:10.2807/ese.18.05.20394-en

Rapid communications Open Access

Like 0

Download

Interim estimates of influenza vaccine effectiveness in 2012/13 from Canada’s sentinel surveillance network, January 2013
D M Skowronski^1,2 , N Z Janjua^1,2 , G De Serres^3,4,5 , J A Dickinson⁶ , A-L Winter⁷ , S M Mahmud^8,9 , S Sabaiduc¹ , J B Gubbay^7,10 , H Charest³ , M Petric^1,2 , K Fonseca^6,11 , P Van Caeseele¹² , T L Kwindt^1,2 , M Krajden^1,2 , A Eshaghi⁷ , Y Li^9,13
View Affiliations Hide Affiliations

Affiliations: ¹ British Columbia Centre for Disease Control, Vancouver, Canada ² University of British Columbia, Vancouver, Canada ³ Institut National de Santé Publique du Québec (National Institute of Health of Quebec), Québec, Canada ⁴ Laval University, Quebec, Canada ⁵ Centre Hospitalier Universitaire de Québec (University Hospital Centre of Quebec), Québec, Canada ⁶ University of Calgary, Calgary, Canada ⁷ Public Health Ontario, Toronto, Canada ⁸ Winnipeg Regional Health Authority, Winnipeg, Canada ⁹ University of Manitoba, Winnipeg, Canada ¹⁰ University of Toronto, Toronto, Canada ¹¹ Alberta Provincial Laboratory, Calgary, Canada ¹² Cadham Provincial Laboratory, Winnipeg, Canada ¹³ National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada

Correspondence:
D Skowronski
danuta.skowronski bccdc.ca
View Citation Hide Citation

Citation style for this article: Skowronski D M, Janjua N Z, De Serres G, Dickinson J A, Winter A-L, Mahmud S M, Sabaiduc S, Gubbay J B, Charest H, Petric M, Fonseca K, Van Caeseele P, Kwindt T L, Krajden M, Eshaghi A, Li Y. Interim estimates of influenza vaccine effectiveness in 2012/13 from Canada’s sentinel surveillance network, January 2013. Euro Surveill. 2013;18(5):pii=20394. https://doi.org/10.2807/ese.18.05.20394-en Received: 21 Jan 2013

Abstract

The 2012/13 influenza season in Canada has been characterised to date by early and moderately severe activity, dominated (90%) by the A(H3N2) subtype. Vaccine effectiveness (VE) was assessed in January 2013 by Canada's sentinel surveillance network using a test-negative case-control design. Interim adjusted-VE against medically attended laboratory-confirmed influenza A(H3N2) infection was 45% (95% CI: 13-66). Influenza A(H3N2) viruses in Canada are similar to the vaccine, based on haemagglutination inhibition; however, antigenic site mutations are described in the haemagglutinin gene. .